Indication-specific pricing of pharmaceuticals in the US healthcare system
AIM: To explore the potential of indication-specific pricing (ISP) of pharmaceuticals and to discuss prospects for implementation in the US healthcare system.
MATERIALS & METHODS: The Institute for Clinical and Economic Review convened a policy forum with 44 healthcare leaders from 22 payer and life sciences companies. Models of ISP were discussed.
RESULTS: Payers and drug manufacturers saw the potential benefits of an ISP system that balances affordability for payers, sustainability for manufacturers and access for patients. The US healthcare system presents many challenges to implementation, including potential conflicts with existing pricing policies (Medicaid Best Price, average sales price and 340B) and insufficient data systems and analytic capabilities.
CONCLUSION: Possible solutions and policy recommendations for payers and manufacturers are provided.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Journal of comparative effectiveness research - 6(2017), 5 vom: 15. Juli, Seite 397-404 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pearson, Steven D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.06.2019 Date Revised 07.06.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/cer-2017-0018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM273759272 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM273759272 | ||
| 003 | DE-627 | ||
| 005 | 20231225001948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/cer-2017-0018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0912.xml |
| 035 | |a (DE-627)NLM273759272 | ||
| 035 | |a (NLM)28699779 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pearson, Steven D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Indication-specific pricing of pharmaceuticals in the US healthcare system |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.06.2019 | ||
| 500 | |a Date Revised 07.06.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: To explore the potential of indication-specific pricing (ISP) of pharmaceuticals and to discuss prospects for implementation in the US healthcare system | ||
| 520 | |a MATERIALS & METHODS: The Institute for Clinical and Economic Review convened a policy forum with 44 healthcare leaders from 22 payer and life sciences companies. Models of ISP were discussed | ||
| 520 | |a RESULTS: Payers and drug manufacturers saw the potential benefits of an ISP system that balances affordability for payers, sustainability for manufacturers and access for patients. The US healthcare system presents many challenges to implementation, including potential conflicts with existing pricing policies (Medicaid Best Price, average sales price and 340B) and insufficient data systems and analytic capabilities | ||
| 520 | |a CONCLUSION: Possible solutions and policy recommendations for payers and manufacturers are provided | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Institute for Clinical and Economic Review | |
| 650 | 4 | |a health policy | |
| 650 | 4 | |a indication-specific pricing | |
| 650 | 4 | |a multi-indication drugs | |
| 650 | 4 | |a payers | |
| 650 | 4 | |a pharmaceutical manufacturers | |
| 650 | 4 | |a reimbursement | |
| 650 | 4 | |a value-based pricing | |
| 650 | 7 | |a Drugs, Generic |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 700 | 1 | |a Dreitlein, William B |e verfasserin |4 aut | |
| 700 | 1 | |a Henshall, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Towse, Adrian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of comparative effectiveness research |d 2012 |g 6(2017), 5 vom: 15. Juli, Seite 397-404 |w (DE-627)NLM218708033 |x 2042-6313 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2017 |g number:5 |g day:15 |g month:07 |g pages:397-404 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/cer-2017-0018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2017 |e 5 |b 15 |c 07 |h 397-404 | ||